Dilemma of COVID-19, aging and cardiovascular disease

What The Viewpoint Says: Whether individuals should continue to take angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the context of coronavirus disease 2019 (COVID-19) is discussed in this article.

Authors: Majd AlGhatrif, M.D., M.A., of the National Institutes of Health in Baltimore, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ 

(doi:10.1001/jamacardio.2020.1329)

Editor’s Note: Please see the articles for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

###

Media advisory: The full article is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2020.1329?guestAccessKey=5ddaab2f-e4a3-4e1b-9b69-c523df1ab830&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=040320

Media Contact
JAMA Network Media Relations

[email protected]

Comments